Beirne Wealth Consulting Services, LLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 106 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Beirne Wealth Consulting Services, LLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q2 2024$44,879
-32.6%
45,0000.0%0.02%
-35.7%
Q1 2024$66,600
+35.8%
45,0000.0%0.03%
+16.7%
Q4 2023$49,050
-22.7%
45,0000.0%0.02%
-52.9%
Q3 2023$63,4500.0%45,0000.0%0.05%0.0%
Q2 2023$63,450
-6.0%
45,0000.0%0.05%
+8.5%
Q1 2023$67,500
+28.2%
45,0000.0%0.05%
+80.8%
Q4 2022$52,650
+3.2%
45,0000.0%0.03%
+36.8%
Q3 2022$51,000
-28.2%
45,0000.0%0.02%
-58.7%
Q2 2022$71,000
+1.4%
45,0000.0%0.05%
+17.9%
Q1 2022$70,000
-36.4%
45,0000.0%0.04%
-35.0%
Q4 2021$110,000
-2.7%
45,0000.0%0.06%
-6.2%
Q3 2021$113,000
-11.7%
45,0000.0%0.06%
-8.6%
Q2 2021$128,000
+20.8%
45,0000.0%0.07%
+12.9%
Q1 2021$106,000
+34.2%
45,0000.0%0.06%
+59.0%
Q4 2020$79,000
+88.1%
45,0000.0%0.04%
+56.0%
Q3 2020$42,000
-31.1%
45,000
-35.7%
0.02%
-50.0%
Q2 2020$61,000
+64.9%
70,000
+55.6%
0.05%
+25.0%
Q1 2020$37,000
-7.5%
45,0000.0%0.04%
+14.3%
Q4 2019$40,000
-9.1%
45,0000.0%0.04%
-5.4%
Q3 2019$44,00045,0000.04%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2022
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$52,403,2283.69%
Raffles Associates 1,536,946$2,305,4193.14%
Defender Capital, LLC. 5,136,085$7,704,1282.69%
Prescott General Partners LLC 1,851,851$2,777,7770.22%
DAFNA Capital Management LLC 140,000$210,0000.06%
Beirne Wealth Consulting Services, LLC 45,000$67,5000.05%
CTC Capital Management, LLC 14,100$21,1500.04%
Diametric Capital, LP 50,875$76,3130.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$1,172,6490.03%
One68 Global Capital, LLC 13,377$20,0660.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders